Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04193878 · ClinicalTrials.gov registry record · Phase 3

ARrest RESpiraTory Failure From PNEUMONIA

A Phase 3 study, sponsored by Stanford University.

Terminated
Registry status
Phase 3
Development phase
465
Enrollment target

NCT04193878: Clinical Trial Phase 3 study, sponsored by Stanford University.

NCT04193878 is a Phase 3 study that was terminated before completion, run by Stanford University. The registered enrollment target is 465 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04193878, a Phase 3 study, was terminated before completion, sponsored by Stanford University.

TERMINATED
Registry status
Phase 3
Development phase
465 participants
Enrollment target

Study Summary

This research study seeks to establish the effectiveness of a combination of an inhaled corticosteroid and a beta agonist compared to placebo for the prevention of acute respiratory failure (ARF) in hospitalized patients with pneumonia and hypoxemia.

Interventions

  • DRUG Inhaled placebo
  • DRUG Inhaled budesonide and formoterol

Trial Details

FieldValue
Enrollment Target 465 participants
Start Date 2020-06-01
Est. Completion 2025-07-22
Phase Phase 3

Sponsor

Stanford University

1,744 total trials

What the Registry Record Tells You About NCT04193878

The ClinicalTrials.gov registry entry for NCT04193878 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 465 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Inhaled placebo is the first listed.

NCT04193878 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04193878 about?

NCT04193878 is a clinical study titled "ARrest RESpiraTory Failure From PNEUMONIA". This research study seeks to establish the effectiveness of a combination of an inhaled corticosteroid and a beta agonist compared to placebo for the prevention of acute respiratory failure (ARF) in hospitalized patients with pneumonia and hypoxemia.

What is the current status of trial NCT04193878?

This trial is currently terminated. It is a Phase 3 study. The enrollment target is 465 participants. The study started on 2020-06-01. Estimated completion is 2025-07-22.

What interventions are being tested in trial NCT04193878?

The interventions under investigation include: Inhaled placebo (DRUG), Inhaled budesonide and formoterol (DRUG).

Who is sponsoring clinical trial NCT04193878?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.